NF-κB transcription factors are key regulators of immune and stress responses, apoptosis, and differentiation. Human cytomegalovirus (HCMV) activates or represses NF-κB signaling at different times during infection. An initial increase in NF-κB activity occurs within a few hours of infection. The virus appears to adapt to this change since initial viral gene expression is promoted by the elevated NF-κB activity. Because NF-κB upregulates innate immune responses and inflammation, it has also been suggested that HCMV needs to downregulate NF-κB signaling. Recent studies have shown that HCMV has various mechanisms that inhibit NF-κB signaling. HCMV reduces cell surface expression of tumor necrosis factor receptor 1 (TNFR1) and blocks the DNA binding activity of NF-κB. Furthermore, some HCMV tegument proteins antagonize NF-κB activation by targeting the key components of NF-κB signaling at late stages of infection. In this review, we summarize the recent findings on the relationship between HCMV and NF-κB signaling, focusing, in particular, on the viral mechanisms by which the NF-κB signaling pathway is inhibited.
INTRODUCTION

Human cytomegalovirus (HCMV)
,
(2) Activation mechanisms observed in clinical strains
The HCMV clinical isolates have a long 15 kb unique region termed UL/b'. Two of the UL/b' region gene products, UL144 and UL138, upregulate the TNFα-mediated NF-κB signaling (19, 20) . UL138, which is expressed during latent infection, modulates the cell surface expression of TNFR1, suggesting that TNF signaling may affect HCMV latency (20, 21) . UL144, which is expressed early in lytic infection, is a transmembrane glycoprotein with a short intracellular cytoplasmic tail. UL144 upregulates chemokine (C-C motif) ligand 22 (CCL22) via the activation of NF-κB in a TRAF6-dependent manner. CCL22 is a chemoattractant for T helper 2 (Th2) and regulatory T (Treg) cells. Therefore, upregulation of NF-κB signaling by UL144 may be a viral strategy to reduce Th1-mediated immune responses (19) .
HCMV functions that inhibit NF-κB signaling
There is increasing evidence that HCMV can also inhibit NF-κB signaling during lytic infection. This negative regulation may be necessary to suppress excessive immune responses that are detrimental to viral infection. Although a viral function in downregulating NF-κB signaling at the early stage of infection has been found, it is believed that the The mechanism by which pp65 inhibits the production of IFNs is controversial. One study demonstrated that pp65 inhibits IRF1 and NF-κB activity (23) , while another study suggested that pp65 inhibits IRF3 activation (24) . It is likely that tegument pp65 rapidly moves to the nucleus after it is delivered to infected cells and suppresses excessive antiviral cellular gene expression at very early times after infection. However, the mechanism by which pp65 inhibits the activation of NF-κB needs to be further investigated.
(3) UL26
UL26 is an early viral protein (25) that initially localizes to the nucleus. As the infection progresses, UL26 becomes cytoplasmic and eventually localizes to virion assembly sites (26) . The mechanism by which UL26 contributes to HCMV replication is largely unknown. It has recently been reported that UL26 is able to antagonize NF-κB activation.
Infection with UL26-deficient virus fails to block the canonical NF-κB activation induced by TNFα, and the expression of UL26 in the absence of other viral proteins is sufficient to block TNFα-induced NF-κB activation. Therefore, UL26 appears to attenuate IKK phosphorylation and subsequent IκBα degradation (27) . 
CLOSING REMARKS
The NF-κB signaling pathway is critical for innate immunity and defense against viruses. Recent studies have shown that HCMV upregulates or downregulates NF-κB signaling at different times of infection (Table 1) However, because NF-κB activation leads to antiviral immune responses and inflammation, it is not surprising that HCMV has also developed strategies to downregulate NF-κB signaling. Indeed, evidence is accumulating that HCMV inhibits NF-κB signaling at late stages of infection.
The viral gene products responsible for this late inhibition of NF-κB signaling have yet to be discovered. Certainly, further information on the interplay between virus and NF-κB signaling will be necessary to understand the pathogenesis of HCMV. 
